
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
MILAN, September 09, 2025 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the LUCE-1 study at the 25th […]